Exploring quality of life and satisfaction with treatment in asthmatic patients receiving dry powder inhalers: a multinational survey.


Journal

The Journal of asthma : official journal of the Association for the Care of Asthma
ISSN: 1532-4303
Titre abrégé: J Asthma
Pays: England
ID NLM: 8106454

Informations de publication

Date de publication:
07 2022
Historique:
pubmed: 5 5 2021
medline: 16 6 2022
entrez: 4 5 2021
Statut: ppublish

Résumé

The quality of life (QoL) and device needs have not been characterized in asthmatic patients treated via dry powder inhalers (DPIs). The aim of this study was to assess the impact of asthma on health-related QoL, device satisfaction, and preference in adult asthmatic patients using DPI devices, and to identify any DPI-associated unmet needs. An online survey was conducted between November and December 2019 on eligible patients from the Cint consumer panel across Europe. Newly designed, as well as validated questionnaires were used to collect data on QoL and inhaler satisfaction. A total of 1063 asthmatic patient took part in the survey; 66% of the patients reported medium or high impact of asthma on the overall QoL. The majority of patients (61%) reported high level of satisfaction with their current device. The patients with medium-to-high impact of asthma on QoL were significantly less likely to be satisfied with their current device (55%) than those who reported low-to-medium impact of asthma on QoL (67%; In asthmatic patients with medium to high impact of asthma on the overall QoL, the satisfaction with the device is highly affected.

Identifiants

pubmed: 33941015
doi: 10.1080/02770903.2021.1923739
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1473-1483

Auteurs

Marco Contoli (M)

Respiratory Section, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.

Sara Barile (S)

Global Medical Affairs, Chiesi Farmaceutici S.p.A, Parma, Italy.

Elena Nudo (E)

Global Medical Affairs, Chiesi Farmaceutici S.p.A, Parma, Italy.

Daniele Guastalla (D)

Global Medical Affairs, Chiesi Farmaceutici S.p.A, Parma, Italy.

Fulvio Braido (F)

Department of Internal Medicine (DiMI), Respiratory Unit for Continuity of Care, IRCCS, Ospedale Policlinico San Martino, University of Genova, Genova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH